Skip to content
2000
Volume 3, Issue 3
  • ISSN: 1872-2148
  • E-ISSN: 2212-3334

Abstract

Liraglutide is a novel glucagon-like peptide 1 analogue, which shows promise as a safe, effective therapy for type 2 diabetes. This review discusses the pathophysiology of type 2 diabetes, focusing on the incretin system, and reviews the pharmacology of liraglutide. A concise discussion of preclinical and clinical data is given, highlighting the benefits of liraglutide with respect to glycaemic control, weight modulation and extraglycaemic effects. This article also review some of recent patents related to the field.

Loading

Article metrics loading...

/content/journals/emi/10.2174/187221409789104719
2009-11-01
2025-10-04
Loading full text...

Full text loading...

/content/journals/emi/10.2174/187221409789104719
Loading

  • Article Type:
    Research Article
Keyword(s): glucagon like peptide-1 (GLP-1); incretins; Liraglutide; type 2 diabetes
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test